Idatha entsha kwi-Relapsed / Refractory Multiple Myeloma Patients

I-Oncolytics Biotech® Inc. namhlanje ibhengeze ukupapashwa kwepowusta ye-elektroniki kwi-American Association for Cancer Research (AACR) iNtlanganiso yoNyaka enedatha entsha yekliniki ye-biomarker evela kuphando olugqityiweyo lwesigaba se-1b sovavanyo lwe-pelareorep kunye ne-proteasome inhibitor bortezomib kwi-relapsed / refractory. izigulane ezininzi ze-myeloma.

"Iziphumo zolu vavanyo zibonelela ngomzekelo onamandla wendlela i-pelareorep's immunologic effects ebangela ngayo inzuzo yeklinikhi ehlala ixesha elide kwizigulane ezicela umngeni," watsho uThomas Heineman, MD, Ph.D., iGosa eliyiNtloko lezoNyango le-Oncolytics Biotech Inc. "Zonke izigulana ababhalise kuphononongo baye basilela unyango lwangaphambili, nangona kunjalo, unyango nge-pelareorep-based therapy luthintele ukuqhubela phambili kwesifo iminyaka engaphezu kwemithathu kwi-subset yezigulane. Ukongeza, olu phononongo lubonisa ukuba amandla e-pelareorep ekufumaneni uxinzelelo oluphezulu lweeseli ezichasene nomhlaza kwi-tumor microenvironment (TME) inokuvelisa iziphumo ezinamandla zeklinikhi. Oku kufunyanisiweyo kuchukumisayo kuneempembelelo kumhlaza ongaphaya kwe-myeloma emininzi njengoko yakhela kwidatha ekhoyo exhasa amandla e-pelareorep okuphucula ukusebenza koluhlu olubanzi lonyango ngokukwazi ukuvuselela i-TME enokudumba. "

Idatha ebikhe yaxelwa ngaphambili ekhankanyiweyo kwipowusta ehambelanayo ne-abstract ibonise ukusebenza kwendibaniselwano efundiweyo kwaye yabonisa iseti ephantsi yabathathi-nxaxheba bolingo abafikelela kwi-prolongsion-free survival (PFS) engaphezulu kweminyaka emithathu (ikhonkco kwi-PR). Ezi nkcukacha zikwabonisa impendulo yeklinikhi ehambelana notshintsho kwi-T cell clonality kunye nokunyuka kwangemva kokunyanga kwiiseli ze-immune zangaphakathi kunye neziguquguqukayo ngaphakathi kwe-TME. Uhlalutyo olutsha lwe-biomarker luboniswe kwipowusta lubonisa ezi seli zokuzikhusela ezichasene nomhlaza zidibana ngokusondeleyo kwiiseli zomhlaza eziqulethe i-pelareorep xa kuthelekiswa nezo zingazange. Ngokudibeneyo, ezi ziphumo zibonisa ukuba izibonelelo zeklinikhi ezizinzileyo ezijongwayo zaqhutywa kukuqeshwa kwe-pelareorep yeeseli ezichasene nomhlaza kwi-TME.

UGqr. Matt Coffey, uMongameli kunye neGosa eliyiNtloko yeSigqeba se-Oncolytics Biotech Inc., uthe, “Olu lingo luvelise idatha ebalulekileyo yobungqina obuqinisekisa iprofayile yokhuseleko encomekayo yepelareorep, sandise ukuqonda kwethu indlela yokusebenza, kunye nokuxhasa ngakumbi ukusetyenziswa. yeT cell clonality njenge biomarker. Ezi zifundo zibalulekileyo zomeleza impembelelo yenkqubo ebonwa kwezinye iiseti zedatha ezixhasa inkqubo nganye yekliniki kwaye zinokusetyenziswa ukukhawulezisa ukuqhubela phambili kwazo. Ukuqhubela phambili, siceba ukusebenzisa iziphumo zethu kwi-myeloma emininzi ukuqhuba iingxoxo kunye namaqabane anokubakho kunye nabasebenzisana nabo abanomdla kwi-leveraging pelareorep's immunotherapeutic effects ukujongana neemfuno ezingafezekanga kule kunye nezinye izibonakaliso. Ngaphakathi, sihlala sigxile kwinkqubo yethu yomhlaza webele kwaye sijonge phambili ekufundweni kwedatha yesigaba sesi-2 esilindelweyo kwikota yesine yonyaka. "

Ipowusta ye-AACR ye-elektroniki, enesihloko esithi, Uhlalutyo Lweseli Eyodwa Lubonisa Ukuba I-Reovirus Immune Priming Itshintsha I-Tumor Immune Micro Environment kwi-Multiple Myeloma, iyafumaneka kubantu ababhalisiweyo bentlanganiso yonyaka ye-AACR kwiwebhusayithi yentlanganiso (Abstract #6354). Ikopi yepowusta nayo iya kuthunyelwa kwiphepha leePosters & Publications kwiwebhusayithi ye-Oncolytics (LINK) emva kokuqukunjelwa kwentlanganiso.